About: X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.28 (-2.38%)
XFOR NASDAQ X4 Pharmaceuticals Inc
X4 Pharmaceuticals Inc share price
XFOR price activity
Last Price
$3.220
Change (24hr)
-0.15 USD (4.32%)
Volume
337.42K
Volume (4w avg)
-
Open
$3.33
Day Range
$3.21 - $3.41
Previous Close
$3.36
Last Trade
30 Oct, 5:01 pm GMT+0
Delayed
30 Oct, 5:01 pm GMT+0
XFOR price performance
Delayed
30 Oct, 5:01 pm GMT+0
XFOR Market Signals